Julie Yeni
Baker McKenzieBaker McKenzie houses a ‘fast, reliable and professional’ practice, which is known for its ’excellent’ expertise in advising global healthcare and biotech corporations on compliance programs, strategic partnerships, and product regulation. Additionally, the group exhibits broad corporate and IP expertise, handling product acquisition arrangements and technology transfer agreements for medtech clients. The ‘exceptional’ Julie Yeni leads the team, and frequently advises healthcare clients on both contentious and non-contentious matters, particularly in relation to market access, clinical trials, and commercialisation.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘A fast, reliable and professional team, as always. A big plus to have them by our side.’
‘Julie Yeni is recommended for her precision, clairvoyance, and her experience. An exceptional professional.’
‘Accessibility, kindness and adaptability.’
‘Excellent expertise, great availability. Customer service-oriented. By far, one of the best pharma law teams in Paris.’
‘Julie Yeni is one of the most recognised lawyers on the Parisian market.’
Key clients
- AbbVie
- BMS - Bristol-Myers Squibb
- Johnson & Johnson
- Laboratoires Servier
Work highlights
- Advised New-York-based investment fund New Mountain Capital on the acquisition of the Applied, Food and Enterprise Services (AES) business of the Discovery & Analytical Solutions division of PerkinElmer Inc.
- Advised Johnson & Johnson, in connection with the spin-out of its consumer healthcare business. In France, this internal reorganization is concretized by notably transferring a manufacturing pharmaceutical establishment from one legal entity to a newly created legal entity within the group.
Lawyers
Next Generation Partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Practice head
The lawyer(s) leading their teams.
Julie Yeni